Health care stocks are poised for strong performance as seasonal trends show a historical uptick from late spring into fall, coinciding with key medical conferences and an environment favoring defensive investments. In 2026, the favorable seasonality aligns with a significant rotation towards defensive sectors amid rising economic uncertainties.
Eli Lilly (LLY) has reported first-quarter 2026 revenues of $19.80 billion, a 56% year-over-year increase, with an adjusted EPS of $8.55, surpassing estimates. The company’s market share in the U.S. obesity and diabetes sectors stands at 60%. Meanwhile, Merck (MRK) posted worldwide sales of $16.29 billion, up 5%, driven by strong performance from its oncology drug Keytruda, which generated nearly $8.0 billion in revenue.
As seasonal factors gather momentum and policy uncertainties dissipate, health care is generating significant interest among investors seeking stability. Both Eli Lilly and Merck are highlighted as potential leaders in the sector amidst these favorable conditions.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
